AU2009288657A1 - Synaptic vesicle cycling assays and systems - Google Patents
Synaptic vesicle cycling assays and systems Download PDFInfo
- Publication number
- AU2009288657A1 AU2009288657A1 AU2009288657A AU2009288657A AU2009288657A1 AU 2009288657 A1 AU2009288657 A1 AU 2009288657A1 AU 2009288657 A AU2009288657 A AU 2009288657A AU 2009288657 A AU2009288657 A AU 2009288657A AU 2009288657 A1 AU2009288657 A1 AU 2009288657A1
- Authority
- AU
- Australia
- Prior art keywords
- platform
- synaptic vesicle
- range
- cells
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002504 synaptic vesicle Anatomy 0.000 title claims description 555
- 230000001351 cycling effect Effects 0.000 title claims description 360
- 238000003556 assay Methods 0.000 title description 64
- 210000002569 neuron Anatomy 0.000 claims description 417
- 238000000034 method Methods 0.000 claims description 173
- 108090000623 proteins and genes Proteins 0.000 claims description 157
- 210000004027 cell Anatomy 0.000 claims description 154
- 102000004169 proteins and genes Human genes 0.000 claims description 151
- 239000003795 chemical substances by application Substances 0.000 claims description 100
- 238000001514 detection method Methods 0.000 claims description 81
- 238000012360 testing method Methods 0.000 claims description 80
- 230000036982 action potential Effects 0.000 claims description 69
- 230000005684 electric field Effects 0.000 claims description 61
- -1 vGlutl Proteins 0.000 claims description 39
- 210000002243 primary neuron Anatomy 0.000 claims description 38
- 150000007523 nucleic acids Chemical group 0.000 claims description 34
- 230000003287 optical effect Effects 0.000 claims description 32
- 108010078791 Carrier Proteins Proteins 0.000 claims description 28
- 238000004113 cell culture Methods 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 108020004459 Small interfering RNA Proteins 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 210000000225 synapse Anatomy 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 20
- 238000001727 in vivo Methods 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 150000003384 small molecules Chemical group 0.000 claims description 18
- 108060008004 synaptotagmin Proteins 0.000 claims description 18
- 102000003137 synaptotagmin Human genes 0.000 claims description 18
- 238000013537 high throughput screening Methods 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 16
- 230000000977 initiatory effect Effects 0.000 claims description 16
- 102000004874 Synaptophysin Human genes 0.000 claims description 15
- 108090001076 Synaptophysin Proteins 0.000 claims description 15
- 238000012544 monitoring process Methods 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 claims description 12
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 claims description 12
- 102100038170 Vesicular inhibitory amino acid transporter Human genes 0.000 claims description 11
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 11
- 229960004373 acetylcholine Drugs 0.000 claims description 11
- 150000003943 catecholamines Chemical class 0.000 claims description 11
- 108010030503 vesicular GABA transporter Proteins 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 102000053642 Catalytic RNA Human genes 0.000 claims description 10
- 108090000994 Catalytic RNA Proteins 0.000 claims description 10
- 230000001800 adrenalinergic effect Effects 0.000 claims description 10
- 230000001713 cholinergic effect Effects 0.000 claims description 10
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 10
- 230000003371 gabaergic effect Effects 0.000 claims description 10
- 230000000848 glutamatergic effect Effects 0.000 claims description 10
- 108091092562 ribozyme Proteins 0.000 claims description 10
- 230000000862 serotonergic effect Effects 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 10
- 238000007654 immersion Methods 0.000 claims description 9
- 239000011810 insulating material Substances 0.000 claims description 9
- 108091006047 fluorescent proteins Proteins 0.000 claims description 8
- 102000034287 fluorescent proteins Human genes 0.000 claims description 8
- 150000002632 lipids Chemical group 0.000 claims description 7
- 239000013642 negative control Substances 0.000 claims description 6
- 239000013641 positive control Substances 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 108091070501 miRNA Proteins 0.000 claims description 3
- 239000002679 microRNA Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 120
- 230000000638 stimulation Effects 0.000 description 113
- 230000003518 presynaptic effect Effects 0.000 description 53
- 230000000694 effects Effects 0.000 description 49
- 241000282414 Homo sapiens Species 0.000 description 38
- 239000000126 substance Substances 0.000 description 36
- 238000003384 imaging method Methods 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 239000000975 dye Substances 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 31
- 239000008194 pharmaceutical composition Substances 0.000 description 31
- 230000012202 endocytosis Effects 0.000 description 30
- 210000000063 presynaptic terminal Anatomy 0.000 description 30
- 241000700159 Rattus Species 0.000 description 28
- 239000012528 membrane Substances 0.000 description 28
- 102000001435 Synapsin Human genes 0.000 description 25
- 108050009621 Synapsin Proteins 0.000 description 25
- 239000011575 calcium Substances 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 24
- 230000005284 excitation Effects 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 238000010304 firing Methods 0.000 description 20
- 230000001537 neural effect Effects 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 241000702421 Dependoparvovirus Species 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 16
- 230000028023 exocytosis Effects 0.000 description 16
- 230000000946 synaptic effect Effects 0.000 description 16
- 210000000170 cell membrane Anatomy 0.000 description 15
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 238000009738 saturating Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000002858 neurotransmitter agent Substances 0.000 description 13
- 102000004631 Calcineurin Human genes 0.000 description 12
- 108010042955 Calcineurin Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000012131 assay buffer Substances 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000004064 dysfunction Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 230000005062 synaptic transmission Effects 0.000 description 10
- 230000009261 transgenic effect Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000004020 conductor Substances 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 238000002952 image-based readout Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 210000004129 prosencephalon Anatomy 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108010019874 Clathrin Proteins 0.000 description 6
- 102000005853 Clathrin Human genes 0.000 description 6
- 108090000862 Ion Channels Proteins 0.000 description 6
- 102000004310 Ion Channels Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 6
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 229930193282 clathrin Natural products 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108010036694 Dynamin I Proteins 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 102000006270 Proton Pumps Human genes 0.000 description 5
- 108010083204 Proton Pumps Proteins 0.000 description 5
- 102000005917 R-SNARE Proteins Human genes 0.000 description 5
- 108010005730 R-SNARE Proteins Proteins 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
- 102000005280 Synaptogyrin Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 210000003618 cortical neuron Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000004941 influx Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 5
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 230000017934 positive regulation of action potential Effects 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000022054 synaptic vesicle endocytosis Effects 0.000 description 5
- 108060008001 synaptogyrin Proteins 0.000 description 5
- 102000000580 synaptojanin Human genes 0.000 description 5
- 108010016910 synaptojanin Proteins 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 108090000312 Calcium Channels Proteins 0.000 description 4
- 102000003922 Calcium Channels Human genes 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 4
- 102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 4
- 102000050389 Syntaxin Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229960003067 cystine Drugs 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108040000979 soluble NSF attachment protein activity proteins Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000003568 synaptosome Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000006854 communication Effects 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 229920001940 conductive polymer Polymers 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000004992 fission Effects 0.000 description 3
- 238000012921 fluorescence analysis Methods 0.000 description 3
- 102000056115 human SYN1 Human genes 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003367 kinetic assay Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 125000005504 styryl group Chemical group 0.000 description 3
- 210000002182 synaptic membrane Anatomy 0.000 description 3
- 230000005657 synaptic vesicle exocytosis Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000575685 Homo sapiens Synembryn-B Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 208000006264 Korsakoff syndrome Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100026014 Synembryn-B Human genes 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 229930192649 bafilomycin Natural products 0.000 description 2
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 238000013481 data capture Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000005279 excitation period Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000012203 high throughput assay Methods 0.000 description 2
- 238000012188 high-throughput screening assay Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 239000012811 non-conductive material Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- BKZOUCVNTCLNFF-IGXZVFLKSA-N (2s)-2-[(2r,3r,4s,5r,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-[(2r,3s,4r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]dec Chemical compound O([C@@H]1[C@@H]2O[C@H]([C@@H](C)[C@H]2OC)[C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](OC)C3)[C@@H](C)[C@@H]3[C@@H]([C@H](OC)[C@@H](C)[C@](O)([C@H](C)C(O)=O)O3)C)CC2)[C@](C)(O)[C@H](C)[C@@H](OC)[C@@H]1C BKZOUCVNTCLNFF-IGXZVFLKSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LMMLLWZHCKCFQA-UGKPPGOTSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C#CC)O[C@H](CO)[C@@H](O)[C@H]1O LMMLLWZHCKCFQA-UGKPPGOTSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 229940121819 ATPase inhibitor Drugs 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100316026 Arabidopsis thaliana UGGT gene Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 102100027557 Calcipressin-1 Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010035848 Channelrhodopsins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150014889 Gad1 gene Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000580357 Homo sapiens Calcipressin-1 Proteins 0.000 description 1
- 101000873786 Homo sapiens Glutamate decarboxylase 2 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical class CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- BKZOUCVNTCLNFF-UHFFFAOYSA-N Lonomycin Natural products COC1C(C)C(C2(C)OC(CC2)C2(C)OC3(OC(C(C)C(OC)C3)C(C)C3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)C)CC2)OC1C1OC(C)(O)C(C)C(OC)C1C BKZOUCVNTCLNFF-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000000583 SNARE Proteins Human genes 0.000 description 1
- 108010041948 SNARE Proteins Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 102100040363 UDP-glucose:glycoprotein glucosyltransferase 1 Human genes 0.000 description 1
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 description 1
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000006117 anti-reflective coating Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004208 basal nucleus of meynert Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000007336 epsin Human genes 0.000 description 1
- 108010032643 epsin Proteins 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 230000000285 glutaminergic effect Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000025350 membrane depolarization involved in regulation of action potential Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002813 septal nuclei Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 201000002959 specific language impairment Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000021966 synaptic vesicle transport Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Electrochemistry (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016202387A AU2016202387A1 (en) | 2008-09-04 | 2016-04-15 | Synaptic vesicle cycling assays and systems |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9436108P | 2008-09-04 | 2008-09-04 | |
| US61/094,361 | 2008-09-04 | ||
| PCT/US2009/004932 WO2010027446A2 (en) | 2008-09-04 | 2009-08-31 | Synaptic vesicle cycling assays and systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016202387A Division AU2016202387A1 (en) | 2008-09-04 | 2016-04-15 | Synaptic vesicle cycling assays and systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2009288657A1 true AU2009288657A1 (en) | 2010-03-11 |
Family
ID=41479300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009288657A Abandoned AU2009288657A1 (en) | 2008-09-04 | 2009-08-31 | Synaptic vesicle cycling assays and systems |
| AU2016202387A Abandoned AU2016202387A1 (en) | 2008-09-04 | 2016-04-15 | Synaptic vesicle cycling assays and systems |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016202387A Abandoned AU2016202387A1 (en) | 2008-09-04 | 2016-04-15 | Synaptic vesicle cycling assays and systems |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120053084A1 (enExample) |
| EP (1) | EP2329275A2 (enExample) |
| JP (2) | JP5789513B2 (enExample) |
| KR (1) | KR20110073494A (enExample) |
| CN (1) | CN102203622A (enExample) |
| AU (2) | AU2009288657A1 (enExample) |
| CA (1) | CA2744804C (enExample) |
| WO (1) | WO2010027446A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011511665A (ja) * | 2008-02-04 | 2011-04-14 | バイエル・ヘルスケア・エルエルシー | 半導体を素材とする分析対象物センサー及び方法 |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US9057734B2 (en) | 2010-08-23 | 2015-06-16 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
| US9207237B2 (en) | 2010-08-23 | 2015-12-08 | President And Fellows Of Harvard College | Systems, methods, and workflows for optogenetics analysis |
| US9488637B2 (en) * | 2011-01-26 | 2016-11-08 | The Curators Of The University Of Missouri | Combination of single-cell electroporation and electrical recording using the same electrode |
| WO2012145624A2 (en) | 2011-04-21 | 2012-10-26 | University Of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| US20150004637A1 (en) * | 2011-11-23 | 2015-01-01 | President And Fellows Of Harvard College | Systems and methods for imaging at high spatial and/or temporal precision |
| US9696275B2 (en) | 2012-10-12 | 2017-07-04 | The Curators Of The University Of Missouri | Addressable electrode arrays in multiple fluidic compartments and uses thereof |
| WO2014065330A1 (ja) | 2012-10-25 | 2014-05-01 | 浜松ホトニクス株式会社 | 細胞観察装置、電気刺激装置、及び細胞観察方法 |
| WO2014065329A1 (ja) * | 2012-10-25 | 2014-05-01 | 浜松ホトニクス株式会社 | 細胞観察装置及び細胞観察方法 |
| JP6370544B2 (ja) * | 2013-11-11 | 2018-08-08 | 浜松ホトニクス株式会社 | 細胞観察装置及び細胞観察方法 |
| EP3095853B1 (en) | 2014-01-16 | 2019-01-30 | Hamamatsu Photonics K.K. | Cell observation device, electrostimulation device, and cell observation method |
| WO2015127128A2 (en) | 2014-02-19 | 2015-08-27 | University Of Massachusetts | Recombinant aavs having useful transcytosis properties |
| DK3119797T3 (da) | 2014-03-18 | 2021-03-15 | Univ Massachusetts | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose |
| JP2017521044A (ja) * | 2014-04-22 | 2017-08-03 | キュー−ステート バイオサイエンシーズ， インコーポレイテッドＱ−Ｓｔａｔｅ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． | 疼痛及び感覚障害のための化合物の分析 |
| US10975391B2 (en) | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
| WO2015195769A2 (en) | 2014-06-18 | 2015-12-23 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
| WO2016033501A1 (en) | 2014-08-28 | 2016-03-03 | Robert John Petcavich | Method of fabricating cell arrays and uses thereof |
| US10711270B2 (en) | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| RU2020140209A (ru) | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| US10077463B2 (en) | 2015-01-15 | 2018-09-18 | President And Fellows Of Harvard College | Optical selection of cells |
| EP3256170B1 (en) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Compositions and methods for transient delivery of nucleases |
| US10048275B2 (en) | 2015-03-13 | 2018-08-14 | Q-State Biosciences, Inc. | Cardiotoxicity screening methods |
| US11020443B2 (en) | 2015-04-23 | 2021-06-01 | University Of Massachusetts | Modulation of AAV vector transgene expression |
| WO2016172008A1 (en) | 2015-04-24 | 2016-10-27 | University Of Massachusetts | Modified aav constructions and uses thereof |
| US11248212B2 (en) | 2015-06-30 | 2022-02-15 | StemoniX Inc. | Surface energy directed cell self assembly |
| US10760053B2 (en) | 2015-10-15 | 2020-09-01 | StemoniX Inc. | Method of manufacturing or differentiating mammalian pluripotent stem cells or progenitor cells using a hollow fiber bioreactor |
| US11426469B2 (en) | 2015-10-22 | 2022-08-30 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| CA3002982A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
| US11826433B2 (en) | 2016-02-02 | 2023-11-28 | University Of Massachusetts | Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system |
| CA3012344A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| EP3225279B1 (en) * | 2016-03-31 | 2023-12-20 | Université de Rennes | Brain tissue stimulation apparatus and computer program |
| WO2017176929A1 (en) | 2016-04-05 | 2017-10-12 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| JP7327803B2 (ja) | 2017-05-09 | 2023-08-16 | ユニバーシティ オブ マサチューセッツ | 筋萎縮性側索硬化症（ａｌｓ）を処置する方法 |
| CN111448321A (zh) | 2017-09-22 | 2020-07-24 | 马萨诸塞大学 | Sod1双表达载体及其用途 |
| CA3096102A1 (en) | 2018-04-13 | 2019-10-17 | University Of Massachusetts | Bicistronic aav vectors encoding hexosaminidase alpha and beta-subunits and uses thereof |
| JP7065433B2 (ja) * | 2018-08-14 | 2022-05-12 | 日本電信電話株式会社 | 電極及びその製造方法、並びに積層体 |
| KR20210087462A (ko) | 2018-10-05 | 2021-07-12 | 유니버시티 오브 매사추세츠 | Gm1 및 gm2 강글리오시드증의 치료를 위한 raav 벡터 |
| SG11202111169YA (en) * | 2019-07-16 | 2021-11-29 | Meso Scale Technologies Llc | Assay apparatuses, methods and reagents |
| EP4271789A4 (en) * | 2020-12-31 | 2024-11-27 | Q-State Biosciences, Inc. | PLATE IMAGE PRODUCER |
| JP2024501848A (ja) | 2020-12-31 | 2024-01-16 | キュー－ステート バイオサイエンシーズ， インコーポレイテッド | 光遺伝学のためのイメージャの較正および正規化 |
| EP4271982A4 (en) * | 2020-12-31 | 2024-11-27 | Q-State Biosciences, Inc. | Optical plate controller and reader |
| EP4271978A4 (en) | 2020-12-31 | 2024-12-18 | Q-State Biosciences, Inc. | MICROSCOPE WITH SPATIAL IMAGING AND BEAM HOMOGENIZER |
| JP2024516303A (ja) * | 2021-05-04 | 2024-04-12 | キュー－ステート バイオサイエンシーズ， インコーポレイテッド | 薬物フィンガプリンティング |
| JP2024525493A (ja) | 2021-06-30 | 2024-07-12 | キュー－ステート バイオサイエンシーズ， インコーポレイテッド | 多重光学刺激および読出 |
| US20250277028A1 (en) * | 2022-04-25 | 2025-09-04 | Jiksak Bioengineering, Inc. | Targeting agent |
| WO2025084395A1 (ja) * | 2023-10-19 | 2025-04-24 | 株式会社Jiksak Bioengineering | 抗シナプトタグミン２抗体 |
| WO2025089346A1 (ja) * | 2023-10-25 | 2025-05-01 | 株式会社Jiksak Bioengineering | 抗シナプトフィジン抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2210911T3 (es) | 1998-07-17 | 2004-07-01 | Vertex Pharmaceuticals (San Diego) Llc | Detector y dispositivo de seleccion para canales ionicos. |
| US6686193B2 (en) * | 2000-07-10 | 2004-02-03 | Vertex Pharmaceuticals, Inc. | High throughput method and system for screening candidate compounds for activity against target ion channels |
| US7615356B2 (en) * | 2000-07-10 | 2009-11-10 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
| WO2003006103A2 (en) | 2001-07-12 | 2003-01-23 | Merck & Co., Inc. | Electrical field stimulation of eukaryotic cells |
| US7221981B2 (en) * | 2002-03-28 | 2007-05-22 | Northstar Neuroscience, Inc. | Electrode geometries for efficient neural stimulation |
| US20070274923A1 (en) | 2005-01-11 | 2007-11-29 | Philippe Brulet | Non-invasive real-time in vivo bioluminescence imaging of local Ca2+ dynamics in living organisms |
-
2009
- 2009-08-31 CN CN2009801440769A patent/CN102203622A/zh active Pending
- 2009-08-31 US US13/062,459 patent/US20120053084A1/en not_active Abandoned
- 2009-08-31 WO PCT/US2009/004932 patent/WO2010027446A2/en not_active Ceased
- 2009-08-31 JP JP2011526037A patent/JP5789513B2/ja not_active Expired - Fee Related
- 2009-08-31 CA CA2744804A patent/CA2744804C/en not_active Expired - Fee Related
- 2009-08-31 KR KR1020117007795A patent/KR20110073494A/ko not_active Ceased
- 2009-08-31 AU AU2009288657A patent/AU2009288657A1/en not_active Abandoned
- 2009-08-31 EP EP09789240A patent/EP2329275A2/en not_active Withdrawn
-
2015
- 2015-07-31 JP JP2015151623A patent/JP6106225B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-15 AU AU2016202387A patent/AU2016202387A1/en not_active Abandoned
-
2018
- 2018-01-11 US US15/868,200 patent/US20180136198A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010027446A2 (en) | 2010-03-11 |
| US20120053084A1 (en) | 2012-03-01 |
| JP2012501646A (ja) | 2012-01-26 |
| JP2016019736A (ja) | 2016-02-04 |
| JP6106225B2 (ja) | 2017-03-29 |
| CA2744804C (en) | 2019-02-05 |
| US20180136198A1 (en) | 2018-05-17 |
| CA2744804A1 (en) | 2010-03-11 |
| WO2010027446A3 (en) | 2010-05-20 |
| JP5789513B2 (ja) | 2015-10-07 |
| EP2329275A2 (en) | 2011-06-08 |
| CN102203622A (zh) | 2011-09-28 |
| KR20110073494A (ko) | 2011-06-29 |
| WO2010027446A4 (en) | 2010-08-05 |
| AU2016202387A1 (en) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2744804C (en) | Synaptic vesicle cycling assays and systems | |
| Koizumi et al. | Structural-functional properties of identified excitatory and inhibitory interneurons within pre-Bötzinger complex respiratory microcircuits | |
| Kuner et al. | A genetically encoded ratiometric indicator for chloride: capturing chloride transients in cultured hippocampal neurons | |
| Jouhanneau et al. | Cortical fosGFP expression reveals broad receptive field excitatory neurons targeted by POm | |
| Dong et al. | Unlocking opioid neuropeptide dynamics with genetically encoded biosensors | |
| JP5953293B2 (ja) | 発光タンパクによる長期モニタリング方法および解析方法 | |
| Gore et al. | Visualization of plasticity in fear-evoked calcium signals in midbrain dopamine neurons | |
| WO2006058014A2 (en) | Harnessing network biology to improve drug discovery | |
| US9012171B2 (en) | Systems and methods for measuring translation activity in viable cells | |
| Hernández‐Ochoa et al. | Disruption of action potential and calcium signaling properties in malformed myofibers from dystrophin‐deficient mice | |
| US20060063202A1 (en) | High throughput method and system for screening candidate compounds for activity against epilepsy and other neurological diseases | |
| EP3042194B1 (en) | Human cellular models with biosensors | |
| Tian et al. | Unlocking opioid neuropeptide dynamics with genetically-encoded biosensors | |
| MX2012003773A (es) | Genes. metodos y composiciones relacionadas con la neurogenesis y su modulacion. | |
| Aleman et al. | Opposing subclasses of Drosophila ellipsoid body neurons promote and suppress sleep | |
| WO2000020859A9 (en) | METHOD AND APPARATUS FOR DETECTING BINDING INTERACTIONS $i(IN VIVO) | |
| HK1162671A (en) | Synaptic vesicle cycling assays and systems | |
| WO2003093442A2 (en) | Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy | |
| Umezawa et al. | Methods of analysis for chemicals that promote/disrupt cellular signaling | |
| Shindo et al. | Genetically encoded sensors for analysing neurotransmission among synaptically-connected neurons | |
| US20030012732A1 (en) | Feeding assay for identifying nematicidal compounds | |
| Faini et al. | Investigating neuronal integration and circuits development via a multicolor labeling strategy | |
| JP5153068B2 (ja) | 生物学的相互作用の解析方法 | |
| LEDRI et al. | ACTIVATING AND RECORDING NEURONAL ENSEMBLES | |
| Aggarwal et al. | Check for updates Chapter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |